971 
Deterioration of Renal Function Associated with Current Level of Immunodeficiency
Ole Kirk*1, A Mocroft2, A d'Arminio Monforte3, A B Eg Hansen4, J Gatell5, S Caplinskas6, G Fatkenheuer7, P Reiss8, E Vinogradova9, J Lundgren1, and the EuroSIDA Study Group
1Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; 2Royal Free and Univ Coll Med Sch, London, UK; 3Hosp San Paulo, Milan, Italy; 4Rigshospitalet, Copenhagen, Denmark; 5Hosp Clin of Barcelona, Spain; 6Lithuanian AIDS Ctr, Vilnius; 7Univ Hosp Cologne, Germany; 8Univ of Amsterdam, The Netherlands; and 9St Petersburg AIDS Ctr, Russia
Background: Deterioration of renal function among
HIV+ patients is recognized to be caused by traditional renal risk
factors, HIV itself, and exposure to ART. The contribution of immunodeficiency
has not been well characterized. Our aim was to
prospectively evaluate the rate of and factors associated with deterioration of
renal function by assessing changes in estimated glomerular fitration rate
(eGFR).
Methods: eGFR was calculated using the
Cockcroft-Gault and modification of diet in renal disease (MDRD) equations
after standardization for body-surface area. Deterioration of renal function
was defined as 2 consecutive eGFR ≤60 mL/minute/1.73 m2 or a
confirmed 25% decline in eGFR. Baseline was defined as the date of the first
eGFR. Multivariable Cox models, stratified by center, were adjusted for
confounders including time-updated exposure to ART, hypertension, diabetes,
smoking, and cardiovascular events.
Results: We included 5526 patients. At baseline the
median age was 43 (IQR 38 to 51), current and nadir CD4 count 453 cells/µL (IQR
310 to 640) and 148 cells/µL (55 to 250), respectively, and 75% had HIV RNA <500
copies/mL. During follow-up, eGFR was measured 31,650 times (5 per patient, IQR
4 to 7; median time between eGFR 4 months (3 to 6), 130 patients (2.4%) with
the mean of the first 2 eGFR >60 experienced a confirmed eGFR ≤60 and
175 patients (3.2%) a confirmed 25% decline in eGFR (incidence rates 13.4
(95%CI 11.1 to 15.7) and 17.3 (14.4 to 19.9)/1000 patient-years of follow-up,
respectively) (see the figure); 41 patients experienced both outcomes. Using
the Cockcroft-Gault equation, a 2-fold higher latest CD4 cell count was
associated with 31% lower risk of developing a confirmed deterioration of renal
function (adjusted relative hazard [RH] = 0.69; 0.55 to 87, p = 0.0034).
CD4 nadir was not associated with deterioration of renal function (RH = 1.03/2-fold
higher; 0.89 to 1.19; p = 0.74). A prior AIDS diagnosis was associated
with increased risk of deterioration of renal function by 75% (RH = 1.75; 1.10
to 2.79; p = 0.018). Hepatitis C virus (HCV) antibody-positive patients
also had an increased risk of deterioration of renal function (RH = 2.67; 1.58
to 4.52; p = 0.0002). Other independent risk factors were diagnosis of a
cardiovascular event, HIV RNA levels, baseline eGFR, and time of inclusion into
the study. Repeating the analysis for a confirmed 25% decline in GFR, the
adjusted RH per doubling of the CD4 cell count was 0.75 (0.64 to 0.88). Similar
results were obtained using the MDRD equation.
Conclusions: Deterioration of renal function occurs
in 2 to 3% of the patients over a period of 2 to 3 years of follow-up, and is
associated with current levels of immunodeficiency, in addition to traditional
risk factors.

|